title: Lenalidomide efficacy in bortezomib-resistant myeloma.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Rosaria
authors.initials: R
authors.lastname: Crupi
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D058186:Acute Kidney Injury / Q000235:genetics; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D017353:Gene Deletion; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide
references.citation: Blood. 2009 Jul 16;114(3):522-5
references.pmid: 19332768
references.citation: Nat Rev Clin Oncol. 2010 May;7(5):289-94
references.pmid: 20351701